'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze
When sell-side analyst Evan Seigerman was preparing to start covering the startup Schrödinger this spring, he rang up the $3.5 billion biotech’s chief financial officer, Geoffrey Porges, to get up to speed.
On the phone with Porges, Seigerman referred to Schrödinger as an AI company. Porges interrupted him: Schrödinger isn’t an AI company — it’s a proprietary software and drug company.
“In my view, that highlighted how they think about what they’re doing,” Seigerman, who tracks biopharma stocks at BMO Capital Markets, told Endpoints News. “They really want to be seen as a drug company that also has this software platform that delivers revenue.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
